EED226

Catalog No.S8496

For research use only.

EED226 is a potent, selective, and orally bioavailable a novel allosteric Polycomb repressive complex 2 (PRC2) inhibitor with an IC50 of 23.4 nM when the H3K27me0 peptide was used as substrate and an IC50 of 53.5 nM when the mononucleosome was used as the substrate. It directly binds to the H3K27me3 binding pocket of EED.

EED226 Chemical Structure

CAS No. 2083627-02-3

Selleck's EED226 has been cited by 15 publications

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Description EED226 is a potent, selective, and orally bioavailable a novel allosteric Polycomb repressive complex 2 (PRC2) inhibitor with an IC50 of 23.4 nM when the H3K27me0 peptide was used as substrate and an IC50 of 53.5 nM when the mononucleosome was used as the substrate. It directly binds to the H3K27me3 binding pocket of EED.
Targets
EED [1]
()
PRC2 [1]
()
82 nM(Kd) 114 nM(Kd)
In vitro

EED226 induces a conformational change upon binding EED, leading to loss of PRC2 activity. EED226 also effectively inhibits PRC2 containing a mutant EZH2 protein resistant to SAM-competitive inhibitors. It regulates histone H3K27 methylation and PRC2 target gene expression in cells. In the in vitro enzymatic assays, EED226 inhibits PRC2 with an IC50 (half-maximal inhibitory concentration) of 23.4 nM when the H3K27me0 peptide is used as substrate and an IC50 of 53.5 nM when the mononucleosome is used as the substrate, with the stimulatory H3K27me3 added at 1 × Kact (1.0 μM). EED226 is noncompetitive with both SAM and peptide substrate. EED226 bound to EED and PRC2 complex with a 1:1 stoichiometry and Kd of 82 nM and 114 nM, respectively. EED226 does not disrupt the PRC2 complex and could still occupy its binding pocket with a SAM-competitive EZH2 inhibitor bound to PRC2. EED226 shows remarkable selectivity for PRC2 complex over 21 other protein methyltransferases, kinases and other protein classes, The only other histone methyltransferase that can be inhibited by EED226 is the EZH1-PRC2 complex. EED226 with moderate permeability leads to a dose-dependent decrease of both global H3K27me3 and H3K27me2 markers in G401 cell[1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KARPAS422 M36zVmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MYj1dEB1dyBzNDDkZZl{ NYrL[nZLSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLRXJRSVN2MkKgZ4VtdHNiaHHyZo9zcW6pIH3vco9idGynbHnjJHk3PDGQIFXaTFIhdXW2YYTpc44h[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IH3lZZN2emWmIHX2[ZJ6KDNidH:gOEBl[Xm|IIXwJJRwKDF2IHThfZMh[nliQnXjb41idiCFb4XseIVzNWKjc3XkJI1mfGixZDygTWM2OCB;IECuNFgh|ryPLh?= Mn\NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhyOUKxOVUoRjJ6MEmyNVU2RC:jPh?=
G401 NHrFXIJHfW6ldHnvckBie3OjeR?= NH\ES4o1QCCqcoO= MkLjTY5pcWKrdHnvckBw\iCHRVSgbY4hcHWvYX6gS|QxOSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6g[4xw[mGuIFizT|I4dWV|IHzleoVtKGGodHXyJFQ5KGi{czDifUBGVEmVQTygTWM2OCB;IECuNlIh|ryPLh?= NIX4fVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEC5NlE2PSd-MkiwPVIyPTV:L3G+
KARPAS422 NWfBd4liSW62aYT1cY9zKGG|c3H5 M4PhXFMxOCCvZz;r[y=> NFryPWI{PCCmYYnz M3HOZ2FvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFvBVnBCWzR{MjDj[YxteyC6ZX7v[5Ji\nSnZDDpckBD[WykL1OgcpVl\SCvb4Xz[UBie3Onc4Pl[EBieyC2dX3vdkBz\We{ZYPzbY9vKGG2IEOwNEBu\y:tZzygdI8hSkmGIH\vdkA{PCCmYYnz M4fqWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEmyNVU2Lz5{OEC5NlE2PTxxYU6=
KARPAS422 M3LtZ2FvfGm2dX3vdkBie3OjeR?= NUDDWYpEOS53IITvJFQxKG2pL3vn MXWyJJdm\Wu| NXzZcVdjSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gT2FTWEGVNEKyJINmdGy|IIjlco9oemGodHXkJIlvKEKjbHKvR{BvfWSnIH3veZNmKGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckB1fW2xcjD2c4x2dWViYYSgNU42KHSxIESwJI1oN2upLDDwc{BDUURiZn;yJFIhf2Wna4O= MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDB7MkG1OUc,OjhyOUKxOVU9N2F-
In vivo EED226 effectively induces tumor regression in a mouse xenograft model. EED226 in a solid dispersion formulation are well tolerated in animals. EED226 clearly demonstrates a dose-dependent efficacy in the mouse xenograph study[1]. EED226 inhibits the growth of diffuse large B-cell lymphoma (DLBCL) xenografts and reduces H3K27me3 levels to a similar extent as an EZH2 inhibitor[2]. EED226 has very low in vivo and in vitro clearance and approximately 100% oral bioavailability, low volume of distribution (0.8 L/kg), reasonable terminal t1/2 (2.2 h), and moderate plasma protein binding (PPB)(14.4%). Its solubility is relatively low and with little dependency on the pH of the medium[3].

Protocol (from reference)

Cell Research:

[1]

  • Cell lines: G401 cells
  • Concentrations: 0.12, 0.37, 1.1, 3.3, 10 μM
  • Incubation Time: 3 d
  • Method:

    G401 cells are treated with EED226 for 3 d at the indicated concentrations. Total histone H3 is shown as a loading control. WB analysis for protein expression of H3K27me3, H3K27me2, H3K27me1.

Animal Research:

[1]

  • Animal Models: Karpas422 xenograft tumors (mouse model)
  • Dosages: 10 ml/kg
  • Administration: oral administration

Solubility (25°C)

In vitro

DMSO 73 mg/mL warmed
(197.61 mM)
Water Insoluble
Ethanol Insoluble

Chemical Information

Molecular Weight 369.40
Formula

C17H15N5O3S

CAS No. 2083627-02-3
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CS(=O)(=O)C1=CC=C(C=C1)C2=CN=C(N3C2=NN=C3)NCC4=CC=CO4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy EED226 | EED226 supplier | purchase EED226 | EED226 cost | EED226 manufacturer | order EED226 | EED226 distributor